Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:35 PM
Ignite Modification Date:
2025-12-24 @ 7:35 PM
NCT ID:
NCT06692803
Eligibility Criteria:
Inclusion Criteria:
* Adult patients who initiated their first treatment with imatinib, dasatinib, nilotinib, or bosutinib (conditional on Food and Drug Administration (FDA) approval dates) with 6 months continuous health plan enrollment prior to the first prescription fill date.
* Patients with 2 or more diagnoses for CML (adult as of the first diagnosis for CML).
* Patients had index date on or after first CML diagnosis.
* Patients had no diagnoses for CML remission/relapse prior to index date.
* Patients had no gastrointestinal stomach tumor (GIST) or chronic myelomonocytic leukemia (CMML) at any time.
* Patients had no medical claims associated with a clinical trial during the baseline period.
* Patients had no hematopoietic stem cell transplantation (HSCT) during the baseline period.
* Patients had no CML-related chemotherapy treatments for accelerated phase (AP)/blast crisis (BC) during the baseline period.
* First treatment cohort:
* Patients started first treatment for CML with imatinib, dasatinib, nilotinib, or bosutinib in 2012 or later.
* Patients had no HSCT during the first treatment baseline period.
* Patients had no CML-related chemotherapy treatment for AP/BC during the first treatment baseline period.
* Second treatment cohort:
* Patients started second treatment for CML with imatinib, dasatinib, nilotinib, or bosutinib in 2012 or later.
* Patients had no HSCT from the first treatment baseline period up to second treatment initiation.
* Patients had no CML-related chemotherapy treatment for AP/BC from the first treatment baseline period up to second treatment initiation.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06692803
Study Brief:
Protocol Section:
NCT06692803